Medical Supplies

Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

Medical Supplies, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Optical, Harrow Health, NASDAQ, Company, Investor, Pharmaceutical industry
Monday, October 25, 2021 - 2:00pm

(telephonic replay through November 16, 2021)

Key Points: 
  • (telephonic replay through November 16, 2021)
    Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company.
  • The Company owns and operates ImprimisRx , one of the nations leading ophthalmology-focused pharmaceutical businesses, and Visionology , a direct-to-consumer eye care subsidiary focused on chronic vision care.
  • Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals , Surface Ophthalmics and Melt Pharmaceuticals , all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinicalstage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals.
  • For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

Biotechnology, Medical Devices, Health, Pharmaceutical, Medical Supplies, Hypoglycemia, Engineering, Neurology, Technology, LinkedIn, Industry, Failure, Merck, Twitter, Person, Perception, Private Securities Litigation Reform Act, FDA, SEC, Communication, Nature, Annual report, Endocrinology, Instagram, CEO, COVID-19, Growth, Nasdaq, Gastroenterology, Acquisition, Neutralizing antibody, Pharmaceutical industry
Monday, October 25, 2021 - 12:30pm

We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect, said Paul R. Edick, Chairman and CEO of Xeris Biopharma.

Key Points: 
  • We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect, said Paul R. Edick, Chairman and CEO of Xeris Biopharma.
  • This is another in a series of collaborations Xeris has undertaken with top 10 pharma companies evaluating the XeriJect technology.
  • However, should Merck exercise the negotiated license agreement, they could be very valuable to Xeris.
  • Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology.

Intelligent Fingerprinting’s Simple Saliva-based COVID-19 Test Now CE Marked and Available for Sale

Medical Supplies, Medical Devices, Health, Infectious Diseases, Other Health, Biotechnology, Prison, COVID-19 testing, Saliva, Transport, Intelligence, Airport, Collection, COVID-19, Multimedia, CE, Gold, Cheek, School, Sale, Gag, Sneeze, Pharmaceutical industry, Vaccine
Monday, October 25, 2021 - 8:16am

Intelligent Fingerprinting has announced that its saliva-based COVID-19 test now carries CE marking and is available for sale.

Key Points: 
  • Intelligent Fingerprinting has announced that its saliva-based COVID-19 test now carries CE marking and is available for sale.
  • The test strip is around 95% lighter than traditional lateral flow devices, reducing the environmental impact of packaging and transportation.
  • Im delighted that our test is now CE marked, and we anticipate strong demand from markets around the world.
  • The screening test is performed by inserting the tip of the test strip into the sample, providing a positive or negative result at 20 minutes.

U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine

Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases
Thursday, October 21, 2021 - 10:49pm

Todays ACIP recommendation follows the FDAs emergency use authorization for a booster dose, which was granted yesterday.

Key Points: 
  • Todays ACIP recommendation follows the FDAs emergency use authorization for a booster dose, which was granted yesterday.
  • The ACIP advises the CDC on the populations and circumstances for which vaccines should be used.
  • The Committee based its recommendation on the totality of scientific evidence shared by the company and reviewed by the FDAs Vaccines and Related Biological Products Advisory Committee (VRBPAC).
  • Click for Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information for more information.

Owens & Minor will Report Third Quarter Financial Results on Wednesday, November 3, 2021

Practice Management, Managed Care, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Other Health, Owens & Minor, Twitter, New, OMI, Patient, PPE, LinkedIn, Company, NYSE, Industry, EDT, Investor relations
Thursday, October 21, 2021 - 9:32pm

Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the third quarter of 2021 on Wednesday, November 3, 2021, before trading begins on the New York Stock Exchange.

Key Points: 
  • Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the third quarter of 2021 on Wednesday, November 3, 2021, before trading begins on the New York Stock Exchange.
  • Later that same morning, the Company will host a conference call at 8:30 a.m. EDT to discuss the results.
  • A vertically-integrated, predominantly Americas-based footprint enables Owens & Minor to reliably supply its self-manufactured surgical and PPE products.
  • For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor .

Global Hot and Cold Therapy Packs Industry (2021 to 2027) - Rising Incidence of Spinal Cord Injuries Benefit Market Prospects - ResearchAndMarkets.com

Medical Supplies, Health, Cold, Cold pack cheese, Growth, COVID-19, CAGR, Hot, Bottled water, Pet
Thursday, October 21, 2021 - 5:57pm

The "Hot and Cold Therapy Packs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hot and Cold Therapy Packs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Cold Packs, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$498.7 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $243.6 Million, While China is Forecast to Grow at 9.9% CAGR
    The Hot and Cold Therapy Packs market in the U.S. is estimated at US$243.6 Million in the year 2020.
  • In the global Moist Therapy Packs segment, USA, Canada, Japan, China and Europe will drive the 5.5% CAGR estimated for this segment.

ESO Partners with Bound Tree Medical to Create Integrated Inventory Management Ecosystem for EMS Agencies and Fire Departments

Other Health, Software, Networks, General Health, Data Management, Law Enforcement, Emergency Services, Technology, Hospitals, Medical Supplies, Other Technology, Health, Public Policy, Government, Safety, Solution, Burn, Hospital, Ecosystem, Industry, EMS, HDE, Partnership, Emergency medical services, Gq alpha subunit, Product management, EHR, ESO, Trauma, Automation, Warehouse
Thursday, October 21, 2021 - 5:08pm

ESO Inventory is a modern, cloud-based inventory management platform to help EMS agencies and fire departments quickly and easily manage supplies and medications.

Key Points: 
  • ESO Inventory is a modern, cloud-based inventory management platform to help EMS agencies and fire departments quickly and easily manage supplies and medications.
  • We are proud to partner with an industry leader like Bound Tree to deliver a revolutionary inventory management platform for EMS agencies and fire departments, said Allen Johnson, Chief Product Officer for ESO.
  • Key Highlights of ESO Inventory include:
    Bound Tree Medical Partnership: Upcoming integration with ESO Inventory to track and manage restocking status quickly and easily.
  • ESO Inventory is a refreshingly intuitive inventory management interface that connects EMS processes for both improved visibility and streamlined workflows.

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

Medical Supplies, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neurology, Nephrology, Solubility, Nucleotide, Invention, Failure, Merck, COVID-19 vaccine, Twitter, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, Drug discovery, Baxter International, Gilead Sciences, Jazz Pharmaceuticals, Roche, Exercise, Amgen, Sanofi, Kidney, Marketing, CEO, Trial of the century, COVID-19, Psychiatry, Program, Pharmacokinetics, News, API, Conditional sentence, Pediatrics, GSK, Risk, China Resources, Toxicity, Janssen, Pharmaceutical industry, Fine chemical
Thursday, October 21, 2021 - 2:00pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.
  • BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles.
  • Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.
  • Ligands OmniAb technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies.

PharmaJet, WHO and BMGF Conduct Somalia Polio Vaccination Campaign

General Health, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, PQS, LinkedIn, Vaccine, Disease, Certification, Vaccination, Caregiver, Child, Immunization, World Health Organization, World, System, Global Polio Eradication Initiative, Sneakers, Review, UNICEF, CE marking, U.S. FDA, Injection, CEO, Use, Awareness, Bill & Melinda Gates Foundation, WHO, Crying, Tropy
Thursday, October 21, 2021 - 2:10pm

The PharmaJet needle-free system was chosen for the Somalia campaign because the published data1 demonstrated improved coverage and user preferences.

Key Points: 
  • The PharmaJet needle-free system was chosen for the Somalia campaign because the published data1 demonstrated improved coverage and user preferences.
  • Additionally, fractional dose delivery, enabled by Tropis, provides a cost-saving alternative to traditional delivery methods and can extend limited stocks.
  • Of the healthcare workers surveyed, 100% said that using needle-free injectors could increase vaccination rates.
  • Chris Cappello, President and CEO, PharmaJet, said, We are pleased to be part of the polio immunization efforts in Somalia to eradicate this terrible disease.

United States Insulin Syringes Market Analysis and Forecasts, 2019-2020 & 2021-2027 - ResearchAndMarkets.com

Medical Supplies, Health, Leading Company, Insulin, US, Industry, Medical device, Pharmaceutical industry
Thursday, October 21, 2021 - 10:20am

The United States Insulin Syringes Market is set to surpass US$ 1 Billion by 2027.

Key Points: 
  • The United States Insulin Syringes Market is set to surpass US$ 1 Billion by 2027.
  • What are the major challenges of the United States insulin syringes market?
  • What is the reimbursement pattern in the United States insulin syringes market?
  • The Leading Companies for the United States Insulin Syringes Market are Listed Below: